CD14

Innate and adaptive immune responses to nanocell-based tumor-targeted cancer therapeutics

Coordinatore	UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS    more  Organization address address: Robert-Koch-Strasse 40 city: GOETTINGEN postcode: 37075 contact info Titolo: Ms. Nome: Christiane Cognome: Hennecke Email: send email Telefono: +49-551 39 8770 Fax: +49-551 39 22593
Nazionalità Coordinatore	Germany [DE]
Totale costo	0 €
EC contributo	330˙100 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IOF-2008
Funding Scheme	MC-IOF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-03-01   -   2013-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS  Organization address address: Robert-Koch-Strasse 40 city: GOETTINGEN postcode: 37075 contact info Titolo: Ms. Nome: Christiane Cognome: Hennecke Email: send email Telefono: +49-551 39 8770 Fax: +49-551 39 22593	DE (GOETTINGEN)	coordinator	330˙100.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'According to the project ‘Fighting against cancer today’ (FACT, funded by the EU 2008), molecularly targeted drugs with associated sophisticated diagnostic systems to personalize care are likely to have a great impact on cancer control in Europe. At the same time, drug delivery is going to be progressed by nanomedicines that can ferry high amounts of active drugs to the tumor. A recent achievement in developing drug delivery systems are bacterially-derived mini- or nanocells that appear to be superior to other nanovector systems, e.g. in terms of stability or packaging versatility, and that aim reaching high therapeutic efficacy with low to no toxicity. This drug-delivery system has been developed by EnGeneIC Pty Ltd in Sydney, Australia. A critical issue of the application of bacterially-derived nanocells to human beings is their inherent capability to provoke adverse immune responses, i.e. via the LPS receptor CD14. Cellular responses to this vector, to be determined as changes in the composition or the activity status of subsets of peripheral blood cells, will be addressed by this proposal. Parallel investigations will yield clues on whether individual genetic variations in molecules determining LPS sensitivity do affect safety and/or efficacy of the delivery system. Moreover, individual genetic variations in drug metabolizing molecules as well as tumor genetics will be assessed in view of therapy outcome predictivity. Research and evaluation of applicability to patients in Europe will be continued at the return host institution, the University Medical Center in Göttingen, which cares for about 13.700 cancer cases yearly, which has a strong focus on molecular tumor diagnostics and individualized medicine within the Department of Gastroenterology, and which provides expertise by experienced specialists as do the German Primate Center or the Max Planck Institutes. Collaborations are strongly envisaged to transfer knowledge most efficiently.'